Thank you, Maria. And yes, I will now comment on the second quarter of 2024. Please note that all numbers presented are in Swedish kronor. Also, I would like to remind you that from the first quarter of this year, Michael has reported in functional reporting and comparable numbers have been adjusted. Furthermore, all organic growth figures are in constant currency, with sales for the cycle amounting to 534 million and an organic growth of -2%. And I will comment more on sales in the next slide. Adjusted EBITDA amounted to 46 million and EBITDA was 36 million for the quarter, which is an improvement compared to the first quarter of 2024.
I also have a separate slide where I will present the EBITDA development during Q2. The gross margin for the quarter amounted to 52%, compared to 46% for the corresponding quarter last year. This can be explained by the product mix and the extraordinary adjustments made in Q2 2023. This is the second quarter we are reporting with the functional reporting structure. The reason why we changed is to increase comparability in the company's cost structure and adapt to the most common market practice.
As mentioned also in the Q1 report, this change has affected the reported gross margin negatively as more costs than before have been included. For example, production staff and depreciation of production equipment, etc., have been included in the reported cost of goods sold instead of OpEx. The net loss for the quarter amounted to -79 million. And if we look into sales for the group for the second quarter, the quarter generated sales of 534 million and a flat total sales growth of -0.6% and a negative organic growth of 2% compared with Q2 2023. The second quarter showed mixed sales performance among our companies, following the same pattern as in Q1, where Biosciences showed good sales levels, especially in the lab automation part of our business and a positive organic growth.
Bioprinting continued to show weaker sales due to dependency on the academia and research segment, as well as softer sales in Asia and foremost in China compared with Q2 2023. Bioautomation science showed improved sales levels compared with Q1 2024. However, Sana was negatively impacted by dependency on the diagnostics segment, and if we move on to profitability, Adjusted EBITDA for Q2 amounted to 46 million, corresponding to a margin of 9%. EBITDA amounted to 36 million, corresponding to a margin of 7%. All business areas were EBITDA positive in Q2.
The improvement compared with the corresponding quarter last year can be explained by lower cost levels, primarily related to personnel. EBITDA trended positively compared with Q1, partially due to seasonality but mainly due to cost-control measures and product mix. As always, staying on course with cost control has been in focus this quarter and will continue to be during the quarters to come. And if we move to the next slide and our cash flow, the cash flow from operating activities for the quarter amounted to -51 million.
This includes a negative effect from changes in net working capital of 54 million. Out of this, 20 million was related to increases in operating receivables. Inventories decreased by 32 million, continuing the trend of decreased inventory levels as also seen by the end of last year and which followed in Q1 this year. Cash flow from changes in operating liabilities decreased by 66 million, which was driven by contract liabilities in biosciences converted to revenue, as well as a decrease in accounts payable. Investments in intangible capital expenditures amounted to 6 million. Several R&D projects have been completed in the second half of 2023, with a reduction in capitalized R&D as a result. Investments in tangible CapEx amounted to 15 million, and we didn't pay out any dividends during the quarter, with total estimated remaining earnout payments amounting to 20 million. Total cash flow during Q2 amounted to -101 million, with cash reserves by the end of June amounting to 688 million. Activities to further strengthen cash flow will continue to be a priority for the group. On the next slide, I will further comment on the development of net working capital. This slide shows the development in net working capital between Q2 2023 and Q2 2024.
During this period, net working capital has decreased from 527 million to 519 million and has been stable around a level of 20 to 25%. Thus, to conclude, we have shown that the actions implemented in 2023 to improve working capital were successful and resulted in our company now having levels of net working capital in line with industry peers. Maria Forss will now comment on our three business areas. Performance in these areas is as follows: